Literature DB >> 9545114

Pentagastrin testing in patients with renal insufficiency: normal responsivity of mature calcitonin.

B Lissak1, E Baudin, R Cohen, N Barbot, A Meyrier, P Niccoli, N Bouyge, E Modigliani.   

Abstract

Calcitonin (CT) is the most sensitive tumor marker for medullary thyroid carcinoma available, but it lacks specificity. Chronic renal failure (CRF) is known to be associated with elevations of serum immunoreactive calcitonin. Using an immunoradiometric assay to detect only mature CT, we evaluated the basal CT level and its response to pentagastrin in 30 patients with CRF and compared these data with those obtained in 71 controls. Basal mature CT was significantly higher (p < 0.05) in patients with CRF (3.55 pg/mL) than in controls (2.00). Among these patients, 20% had basal CT levels more than 10 pg/mL with a maximum of 51 pg/mL. Peak CT values (highest value obtained 3 or 5 minutes after pentagastrin) were comparable in the two groups. Among patients with CRF, 10% had peak CT values greater than 30 pg/mL with a maximum of 53 pg/mL. In this group of patients, no correlation was found between CT (at any time during the test) and parathyroid hormone, calcium, phosphate, or creatinine clearance. Men had significantly higher CT values compared with women at each time point tested, including peak values. Patients with CRF, who have not yet undergone dialysis, have moderately elevated basal CT levels, but have normal pentagastrin-stimulated peak CT levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9545114     DOI: 10.1089/thy.1998.8.265

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  3 in total

1.  Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma.

Authors:  Claire Bléchet; Pierre Lecomte; Loïc De Calan; Patrice Beutter; Serge Guyétant
Journal:  Virchows Arch       Date:  2007-02-28       Impact factor: 4.064

2.  LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.

Authors:  G H Daniels; L Hegedüs; S P Marso; M A Nauck; B Zinman; R M Bergenstal; J F E Mann; J Derving Karsbøl; A C Moses; J B Buse; R M Tuttle
Journal:  Diabetes Obes Metab       Date:  2015-02-23       Impact factor: 6.577

Review 3.  Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Marcelo Augusto Santos; Marcos R Tavares; Rodrigo A Toledo; Joya Emilie de Menezes Correia-Deur
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.